Comparison of Kezar Life Sciences Inc. (KZR) and Stemline Therapeutics Inc. (NASDAQ:STML)

Both Kezar Life Sciences Inc. (NASDAQ:KZR) and Stemline Therapeutics Inc. (NASDAQ:STML) are Biotechnology companies, competing one another. We will compare their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kezar Life Sciences Inc. N/A 0.00 23.17M -1.05 0.00
Stemline Therapeutics Inc. N/A 1177.57 85.02M -3.00 0.00

Table 1 demonstrates Kezar Life Sciences Inc. and Stemline Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Kezar Life Sciences Inc. 0.00% 0% 0%
Stemline Therapeutics Inc. 0.00% -114.5% -90.2%


Kezar Life Sciences Inc.’s Current Ratio and Quick Ratio are 32.9 and 32.9 respectively. The Current Ratio and Quick Ratio of its competitor Stemline Therapeutics Inc. are 4.6 and 4.6 respectively. Kezar Life Sciences Inc. therefore has a better chance of paying off short and long-term obligations compared to Stemline Therapeutics Inc.

Analyst Ratings

In next table is shown Kezar Life Sciences Inc. and Stemline Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kezar Life Sciences Inc. 0 0 0 0.00
Stemline Therapeutics Inc. 0 0 4 3.00

Competitively the consensus price target of Stemline Therapeutics Inc. is $29, which is potential 100.83% upside.

Insider & Institutional Ownership

Institutional investors owned 49.1% of Kezar Life Sciences Inc. shares and 51.3% of Stemline Therapeutics Inc. shares. 12.65% are Kezar Life Sciences Inc.’s share owned by insiders. On the other hand, insiders owned about 9.4% of Stemline Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kezar Life Sciences Inc. -0.34% 13.07% -20.02% 17.87% 0% -14.19%
Stemline Therapeutics Inc. -4.36% 3.16% 8.46% -31.27% -31.88% 20.11%

For the past year Kezar Life Sciences Inc. has -14.19% weaker performance while Stemline Therapeutics Inc. has 20.11% stronger performance.


On 5 of the 8 factors Kezar Life Sciences Inc. beats Stemline Therapeutics Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.